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Abstract
The polymyxin antibiotics [colistin and polymyxin B (PMB)] are increasingly used as a last-line 
option for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria. 
Despite having similar structures and antibacterial activity in vitro, the two clinically available 
polymyxins have very different pharmacological properties, as colistin (polymyxin E) is 
intravenously administered to patients in the form of an inactive prodrug colistin 
methanesulphonate (sodium). This review will discuss recent progress in the pharmacokinetics/
pharmacodynamics and toxicity of colistin and PMB, the factors that affect their pharmacological 
profiles, and the challenges for the effective use of both polymyxins. Strategies are proposed for 
optimising their clinical utility based upon the recent pharmacological studies in vitro, in animals 
and patients. In the ‘bad bugs, no drugs’ era, polymyxins are a critically important component of 
the antibiotic armamentarium against difficult-to-treat Gram-negative ‘superbugs’. Rational 
approaches to the use of polymyxins must be pursued to increase their effectiveness and to 
minimise resistance and toxicity.
Keywords
Polymyxins; Pharmacokinetics; Pharmacodynamics; Nephrotoxicity
*Corresponding author. Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, 19 Innovation 
Walk, Melbourne, VIC 3800, Australia. Fax: +61 3 9902 9222. Colistin.Polymyxin@gmail.com (J. Li). 
Competing interests: None declared.
Ethical approval: Not required.
HHS Public Access
Author manuscript
Int J Antimicrob Agents. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:
Int J Antimicrob Agents. 2016 December ; 48(6): 592–597. doi:10.1016/j.ijantimicag.2016.09.010.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1. Introduction
Colistin (polymyxin E) and polymyxin B (PMB) are lipopeptide antibiotics with activity 
against many Gram-negative bacteria [1,2]. The polymyxins were approved for clinical use 
in the late 1950s but fell out of favour during the mid-1970s owing to concerns over their 
potential to cause nephrotoxicity and neurotoxicity [3]. Over the last two decades, clinical 
interest in polymyxins has increased due to the emergence of extensively drug-resistant 
Gram-negative bacteria coupled with the dry antibiotic development pipeline [1]. Colistin 
and PMB are currently considered a last-line defence against the problematic Gram-negative 
‘superbugs’, notably carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa and 
Acinetobacter baumannii, which are classified under ‘Urgent’ or ‘Serious’ threat level by the 
US Centers for Disease Control and Prevention (CDC) [4]. It is used against these pathogens 
that will be the focus of this mini-review.
Colistin and PMB possess very similar chemical structures, differing only by one amino acid 
at position 6 in the peptide ring, with a D-leucine and D-phenylalanine, respectively [5]. Not 
surprisingly, they have very similar antimicrobial spectra and resistance mechanisms [6]. A 
major difference between the polymyxins is the form in which they are administered 
parenterally. Colistin is administered in the form of an inactive prodrug, colistin 
methanesulphonate (CMS) (a polyanion at physiological pH), while PMB (a polycation at 
physiological pH) is administered directly as its active form [1]. The different chemical 
forms administered have significant impacts on their pharmacokinetics and toxicity [7]. For 
optimal use of CMS/colistin and PMB, it is important to understand their pharmacological 
differences. In this mini-review, we will discuss the latest progress in the pharmacokinetics/
pharmacodynamics and toxicity of colistin and PMB as well as the challenges for optimal 
use of both polymyxins.
2. Different labelling of polymyxin products
Undoubtedly, a major contributing factor to the confusion surrounding the effective use of 
CMS is differences in the dosing terminology [2]. In many parts of the world, such as 
Europe and India, International Units (IU) are used, whereas in North and South America, 
Southeast Asia and Oceania colistin base activity (CBA) is used [1,2]. One million IU 
(MIU) of CMS is equal to ca. 80 mg of CMS or 34 mg of CBA; a more detailed discussion 
on differences in labelling and dosage recommendations can be found in our previous 
reviews [1,2]. Understanding the labelling differences is critical for the optimal use of CMS 
in patients. For PMB, which is available in North and South America, Southeast Asia and 
Japan, all products are labelled using IU (1 mg = 10 000 IU).
3. Minimum inhibitory concentrations (MICs) and mode of action
As CMS is an inactive prodrug of colistin, colistin sulphate should be used in MIC 
measurements for colistin [1]. To date, SENTRY Antimicrobial Surveillance Program 
(2006–2009) is the largest surveillance programme examining the MICs of the polymyxins. 
The compiled data from this programme showed that PMB and colistin have similar in vitro 
activities (MIC90, ≤0.5–1 mg/L) against P. aeruginosa, A. baumannii and Klebsiella 
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pneumoniae, with very low resistance rates globally (<0.1–1.5%) [8]. However, questions 
have been raised regarding the susceptibility testing methods used for polymyxins, including 
their potential adsorption to plastic devices used in the MIC measurement and poor diffusion 
of polymyxins in agar [9]. In this regard, polysorbate 80 (P-80) was initially proposed to 
improve the broth microdilution MIC results for colistin and PMB as it can prevent the 
binding of polymyxins to plastic panels. However, its use was contraindicated by the 
Clinical and Laboratory Standards Institute (CLSI) owing to potential synergism between 
P-80 and the polymyxins [9,10]. In the most recent CLSI protocol, P-80 is not recommended 
in the measurement of colistin and PMB MICs. Presently, broth microdilution is regarded as 
the best method for polymyxin susceptibility testing. Susceptibility breakpoints for colistin 
and PMB set by the CLSI for P. aeruginosa, Acinetobacter spp. and other non-
Enterobacteriaceae are identical, where an MIC of ≤2 mg/L is regarded as susceptible [11]. 
The susceptibility breakpoints of colistin by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) are ≤4 mg/L for Pseudomonas spp. and ≤2 mg/L for 
Acinetobacter spp. and Enterobacteriaceae [12]. However, as will be discussed in Section 5 
below on pharmacodynamics, data from recent pharmacokinetic/pharmacodynamic (PK/PD) 
studies suggest the breakpoints for the above Gram-negative pathogens could be even lower. 
Consequently, a joint CLSI and EUCAST Working Group is currently re-evaluating the 
existing breakpoints [1,9].
The precise mechanism of action of the polymyxins is currently unclear. However, it is 
believed that activity is related, in part, to disruption of the bacterial outer and inner 
membranes via a ‘self-promoted uptake’ mechanism [13]. The initial step involves binding 
of the positively charged polymyxins to negatively charged lipopolysaccharide (LPS) on the 
outer membrane of Gram-negative bacteria both via electrostatic and hydrophobic 
interactions (Fig. 1) [5]. Bacteria can become resistant to polymyxins by modifications of 
the negatively charged phosphate groups of lipid A [14] or by loss of LPS [15]. For more 
details, we direct the reader to the review in this Theme Issue on the mechanism of 
polymyxin resistance.
4. Pharmacokinetics of polymyxins
4.1. Colistin methanesulphonate/colistin
The positively charged colistin exhibits a markedly different PK profile to that of the 
sulfomethylated derivative [1]. CMS is eliminated predominantly by the kidneys, whereas 
colistin is mainly cleared by a route other than renal excretion [2]. Following parenteral 
administration of CMS, colistin is generally formed slowly, with the plasma concentration 
increasing slowly. Plachouras et al. [16] showed that it can take >36 h to reach a colistin 
steady-state plasma concentration of 2 mg/L with intravenous (i.v.) administration of 3 MIU 
CMS every 8 h (q8h) in patients with good renal function. This finding highlights that the 
low initial exposure to formed colistin is a significant PK/PD challenge for optimising CMS 
use in patients. This dilemma can be partially counteracted with the use of a loading dose. In 
studies that evaluated CMS loading doses of 6 MIU and 9 MIU, the average colistin plasma 
concentrations reached 1.34 mg/L and 2.65 mg/L, respectively, at 8 h after the loading dose, 
with the likelihood of earlier eradication of the infecting bacteria [17,18]. In critically ill 
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patients, kidney function and renal replacement therapy (RRT) have a dramatic impact on 
the pharmacokinetics of CMS and formed colistin [19,20]. One of the largest population PK 
studies reported thus far in critically ill patients involved 105 patients with varying degrees 
of renal function [creatinine clearance (CLCr) of 3–169 mL/min/1.73 m2], including 12 
patients on intermittent haemodialysis and 4 on continuous RRT (CRRT) [19]. Even though 
there was only a ca. 5.5-fold range in the daily doses (2.5–13.7 MIU), substantial 
interpatient variation (0.48–9.38 mg/L, ca. 19.5-fold) in the average steady-state plasma 
colistin concentration (Css,avg) was observed in the 105 patients. Significant interpatient 
variation was observed even among patients with similar CLCr and those receiving the same 
daily dose of CMS (Fig. 2). In patients on RRT, both CMS and formed colistin were cleared 
[19,20]. Clearly, given that the plasma concentration of formed colistin is highly influenced 
by renal function, it is essential that the dosage regimen of CMS is adjusted in patients with 
varying renal function to ensure that appropriate colistin exposure is obtained. In patients 
with a CLCr of >80 mL/min, only 65–75% of patients receiving the approved updated dose 
recommended by the US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) achieved a Css,avg of formed colistin ≥1 mg/L [22]. As the MIC90 for 
colistin is ≤0.5–1 mg/L against P. aeruginosa, A. baumannii and K. pneumoniae [8], it would 
be clinically useful to administer the maximal CMS dose in patients with CLCr > 80 mL/
min, ideally in combination with another antibiotic that may provide synergistic bacterial 
killing [19,23]. As colistin is ca. 50% unbound in human plasma [23] (and unpublished 
data), a colistin Css,avg of ca. 2 mg/L is necessary for effective treatment of bacteria with an 
MIC of 1 mg/L. For patients on RRT, in order to achieve a colistin Css,avg of 2 mg/L, the 
current recommendation suggests a CMS loading dose of 9 MIU followed at 24 h by 1 MIU 
every 12 h (q12h) for patients on intermittent haemodialysis, and 4.3 MIU q8h or 6.3 MIU 
q12h for patients on CRRT [19]. Furthermore, haemodialysis patients should aim to have 
their dialysis performed towards the end of the CMS dosing interval to avoid excessive 
removal of CMS from the body. After dialysis, a CMS dose of 1.7 MIU is required to 
replenish the removed CMS.
Currently, little is known about the pharmacokinetics of CMS and formed colistin in 
extravascular sites. In critically ill patients with and without central nervous system (CNS) 
infection, the distribution of colistin into the cerebral spinal fluid (CSF) appears to be very 
low following i.v. CMS administration. In a study by Ziaka et al. [24], the CSF 
concentrations of formed colistin (at 1, 4 and 8 h) following i.v. administration of 3 MIU 
CMS q8h were only ca. 7% of the total serum colistin concentrations in patients without 
CNS infection and ca. 11% in patients with external ventricular drain-associated ventriculitis 
(EVDV). When a combination of i.v. (3 MIU CMS q8h) and intraventricular (0.125 MIU 
CMS once daily) CMS was administered to patients with EVDV, concentrations of formed 
colistin in the CSF were ca. 1.45, 0.84 and 0.62 mg/L, respectively, at 1, 4 and 8 h and were 
>40% of the total colistin serum concentration at each time point [24]. It is evident that the 
combination of i.v. and intraventricular CMS may be useful for the treatment of CNS 
infection caused by Gram-negative bacteria; however, further clinical studies are required.
A recent study in cystic fibrosis (CF) patients showed that the concentration of formed 
colistin in sputum following i.v. administration of CMS is minimal. When six patients with 
CF were administered an i.v. CMS dose of 5 MIU at 3 days post-nebulisation of 4 MIU of 
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CMS, the formed colistin concentrations in the sputum over 12 h were similar to their 
carryover concentrations in the pre-dose sputum (0.12–0.72 mg/L) [25]. Higher 
concentrations (>10-fold) of formed colistin in the sputum were achieved via inhalation (4 
MIU/day of CMS). After a single inhalation dose, an average maximum colistin 
concentration of ca. 6.0 mg/L was achieved in the sputum at ca. 3 h for 2 MIU of CMS and 
ca. 12.8 mg/L at ca. 4.6 h for 4 MIU of CMS [25]. However, plasma concentrations of CMS 
and formed colistin were very low following inhalation. Following a single nebulisation dose 
of CMS at 2 MIU or 4 MIU, the maximum plasma CMS concentrations were 0.22 ± 0.055 
mg/L at ca. 1.3 h and 0.33 ± 0.092 mg/L at ca. 1.9 h, respectively, with <3% of the nebulised 
CMS dose recovered in the urine by 24 h. In a study comparing the intrapulmonary and 
systemic pharmacokinetics of formed colistin in critically ill patients following 
administration of 2 MIU of CMS via inhalation, the steady-state colistin concentrations in 
the epithelial lining fluid were much higher than the steady-state plasma colistin 
concentrations (9.53–1137 mg/L vs. 0.15–0.73 mg/L) [26]. These findings highlight the 
potential to administer CMS by inhalation for the treatment of Gram-negative bacterial 
pneumonia, maximising the exposure of formed colistin in the lungs while minimising 
plasma concentrations and associated systemic toxicity. Clearly, further PK/PD studies are 
warranted for optimising the use of inhaled CMS.
4.2. Polymyxin B
Compared with CMS, only a very small number of studies have examined the 
pharmacokinetics of PMB following i.v. administration. One study involving eight critically 
ill patients showed that PMB is mainly eliminated by non-renal pathway(s), with <1% 
recovered in the unchanged form in urine [27], which is very similar to colistin in rats [28]. 
The largest population PK study to date involved 24 critically ill patients with a wide range 
of kidney function (CLCr of 10–143 mL/min), including two patients on CRRT [29]. With 
i.v. doses ranging from 0.45 mg/kg/day to 3.38 mg/kg/day (i.e. ca. 7.5-fold), the PMB 
Css,avg ranged from 0.68 mg/L to 4.88 mg/L (ca. 7.2-fold) (Fig. 3) and the median urinary 
recovery (4.04%) was very low. The PMB clearance scaled by total body weight from this 
study showed minimal interpatient variability in the PMB Css,avg (range, 0.02–0.06 L/h/kg; 
ca. 3-fold), a finding in marked contrast to the influence of renal function on the Css,avg of 
plasma colistin following administration of CMS as discussed above. Thus, renal function 
does not markedly affect PMB plasma concentrations and should not be used for dose 
adjustment. In the two patients on CRRT, 12.2% and 5.62% of the dose was recovered as 
unchanged PMB in the dialysates during the 12-h dosing interval [29]. Similar to colistin, 
PMB is cleared during dialysis; however, dosage adjustments are currently not 
recommended for patients on CRRT owing to limited clinical data. A National Institutes of 
Health (NIH)-funded clinical study is investigating the PK, PD and toxicodynamic (TD) 
relationships of i.v. PMB in critically ill patients, which aims to develop scientifically-based 
dosing recommendations for this important polymyxin antibiotic (NCT02682355, http://
www.clinicaltrials.gov). In addition, little is known about the distribution of PMB into 
extravascular sites following i.v. administration, and studies in this area will be essential to 
determine the usefulness of i.v. PMB for the treatment of infections such as pneumonia and 
meningitis.
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In summary, the pharmacokinetics of CMS/colistin is influenced by renal function, with 
dosage regimens requiring adjustment in different types of patients. However, such an 
adjustment is not required for PMB, which is mainly cleared by non-renal pathway(s). As it 
is difficult to achieve a Css,avg of even 1 mg/L in patients with good renal function following 
i.v. administration of CMS [19], PMB may be a better option for treatment of bloodstream 
infections, with less interpatient variability and higher Css,avg [7,29]. Since CMS is mainly 
eliminated by the kidneys with high levels of colistin produced in the urinary tract, it may be 
a better option than PMB for the treatment of urinary tract infections. Inhaled CMS has been 
successfully employed for the treatment of lung infections caused by P. aeruginosa in 
patients with CF over the last three decades [30]. Given that inhaled PMB has been 
associated with a greater incidence of local airway irritation compared with CMS [31], CMS 
may be a better choice for inhalation. Nevertheless, prospective randomised controlled 
clinical studies are warranted to compare the efficacy of both polymyxins for the treatment 
of different types of infections.
5. Pharmacodynamics of polymyxins
Most studies examining the pharmacodynamics of the polymyxins have been conducted 
using colistin [23,32–34]. In in vitro studies, colistin shows rapid concentration-dependent 
killing against A. baumannii, K. pneumoniae and P. aeruginosa, with a minimal post-
antibiotic effect at clinically achievable concentrations [32–34]. However, despite rapid 
initial killing, re-growth often occurs quickly (as early as within 2 h of the initial exposure). 
PMB displays very similar pharmacodynamics to that of colistin, with similar rapid killing 
against A. baumannii, K. pneumoniae and P. aeruginosa in vitro, followed by rapid re-
growth [35–37]. In polymyxin-heteroresistant strains, amplification of polymyxin-resistant 
subpopulations has been shown to play an important role in the rapid emergence of 
resistance [38–40]. An inoculum effect has been reported both with colistin and PMB in 
vitro [37,40].
Using P. aeruginosa and A. baumannii in neutropenic mouse thigh and lung infection 
models, the PK/PD index that best describes the antimicrobial activity of colistin is the ratio 
of the area under the unbound (free) concentration–time curve to the MIC (fAUC/MIC) (Fig. 
4) [23]; for P. aeruginosa, this has also been demonstrated in vitro [34]. Owing to the 
potential binding of polymyxins to the plasticware or ultrafiltration membranes, our group 
identified that ultrafiltration can be problematic [28], and ultracentrifugation and rapid 
equilibrium dialysis methods are superior for measuring plasma binding of polymyxins [23]. 
Our recent PK/PD study using ultracentrifugation and rapid equilibrium dialysis methods in 
neutropenic mice showed that the unbound fraction of colistin of 0.084 is ca. 6-fold lower 
than in humans (ca. 0.5) [23] (and unpublished data). For three strains of P. aeruginosa 
[ATCC 27853, PAO1 and a multidrug-resistant (MDR) clinical isolate] and three strains of 
A. baumannii (ATCC 19606 and two MDR clinical isolates), an fAUC/MIC value of 7.4–
13.7 and 7.4–17.6, respectively, was required for a 2 log10 reduction in bacterial load in the 
thigh of neutropenic mice. In the neutropenic mouse lung infection model, subcutaneous 
colistin was substantially less effective at killing P. aeruginosa and A. baumannii compared 
with in the thigh infection model [23]. With the highest tolerable dose (40 mg/kg 
administered 6- or 8-hourly with cumulative daily doses of 120–160 mg/kg), 2 log10 killing 
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in the lungs was not achievable for all six of the tested strains. The lower antibacterial 
activity in the lungs relative to the thigh is most likely due to limited drug exposure in the 
lungs following parenteral administration. Currently available data from animal and clinical 
studies suggest that colistin (and CMS) may have limited efficacy against respiratory tract 
infections [23,25].
Limited studies to date have examined the PK/PD index driving the activity of PMB. Given 
the similarity in the structure, it is very likely that fAUC/MIC is the most predictive PK/PD 
parameter for parenteral PMB [37]. In patients with good renal function, however, 
administration of PMB is very likely to generate higher fAUC/MIC values than CMS 
because: (i) CMS distribution is influenced by kidney function while PMB is not; and (ii) 
CMS conversion to colistin in vivo is slow and incomplete. To optimise the clinical use of 
PMB, more PD studies are needed.
6. Toxicodynamics of polymyxins
In the early years of their use, polymyxin-associated neurotoxicity occurred in patients with 
an incidence as high as 27% following parenteral administration [3,41]. However, recent 
retrospective clinical studies have not shown neurotoxicity to be a major concern [42,43]. 
Nephrotoxicity is by far the most common and dose-limiting side effect associated with 
parenteral polymyxins, with incidence rates in patients as high as 60% [44,45]. However, the 
rate of nephrotoxicity in patients receiving i.v. polymyxins is somewhat variable and 
depends on the definition of nephrotoxicity employed [e.g. RIFLE (risk, injury, failure, loss, 
and end-stage kidney disease) and AKIN (Acute Kidney Injury Network) scoring systems] 
[46].
Nephrotoxicity has been observed both with colistin and PMB following parenteral 
administration [46–49]. Recent TD analyses of colistin showed that patients with colistin 
Css,avg > 2.5 mg/L and patients with CLCr > 80 mL/min are more likely to develop 
nephrotoxicity [47,48]. The minimum colistin plasma concentration was also identified as an 
independent risk factor for nephrotoxicity, which occurred in the majority of patients when 
the minimum colistin plasma concentration was ≥2.2 mg/L (odds ratio = 4.6 on Day 7) [47]. 
For PMB, a daily dose of ≥150 mg (hazard ratio = 1.92) has been identified as the risk factor 
of nephrotoxicity [49]. A retrospective study showed the earliest onset of nephrotoxicity 
reported for i.v. CMS or PMB occurred 2 days after initiation of therapy, with the majority 
of cases occurring after 15 days of therapy [46]. Fortunately, polymyxin-associated 
nephrotoxicity was, however, reversible in most patients [47,50].
With regard to the mechanism of polymyxin-induced nephrotoxicity, cell culture and animal 
studies have demonstrated that colistin and PMB accumulate in renal tubular cells possibly 
through active uptake mechanisms mediated by megalin and PEPT2 transporters [51,52]. 
The resultant extremely high intracellular concentration of polymyxins in renal tubular cells 
causes dramatic changes in the morphology of mitochondria, loss of cytoplasmic membrane 
potential, apoptosis and cell cycle arrest [53,54]. The precise mechanisms of the uptake of 
polymyxins by renal tubular cells and subsequent cell death remain unanswered. However, 
elucidating these mechanisms is crucial for optimising their use in patients, development of 
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novel approaches to attenuate polymyxin-induced nephrotoxicity, and the discovery of safer 
new-generation polymyxins.
7. Conclusions
Significant progress in understanding the pharmacology of polymyxins has been made over 
the past 15 years, although many gaps still remain. Scientifically-based dosing 
recommendations have now been developed for i.v. administration of CMS in critically ill 
patients and more recent studies are generating valuable insights for PMB. It is evident now 
that only the dose of CMS/colistin, not PMB, should be adjusted according to the patient’s 
renal function. As CRRT can efficiently eliminate both colistin and PMB, further clinical 
PK/PD/TD studies are warranted in order to optimise their use in this type of patient. Other 
high-priority research areas include evaluation of the efficacy of i.v. CMS/colistin and PMB 
for the treatment of respiratory tract infections and clinical PK/PD/TD studies of intrathecal 
and intraventricular administration of both polymyxins for the treatment of meningitis. 
While we await the development of novel antibiotics for the treatment of infections caused 
by Gram-negative ‘superbugs’, every effort must be made to optimise the clinical use of the 
polymyxins to maximise their efficacy while minimising the emergence of resistance and 
toxicity.
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Fig. 1. 
Schematic diagram showing key contacts involved in the complex formation between 
polymyxin B and the lipid A component of lipopolysaccharide. FA, N-terminal fatty acyl 
chain; OM, outer membrane. Figure reproduced from Velkov et al. [5] with permission. 
Published 2010 by the American Chemical Society.
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Fig. 2. 
Relationship of physician-selected daily dose of colistin base activity (CBA) (A) and the 
resultant average steady-state plasma colistin concentration (B) versus creatinine clearance 
(CLCr) in 105 critically ill patients. CLCr was calculated using the Jelliffe equation [21]. 
Figure reproduced from Garonzik et al. [19] with permission. Published 2011 by the 
American Society for Microbiology.
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Fig. 3. 
Plasma concentration–time profiles of polymyxin B in 24 critically ill patients. 
Concentrations from patients undergoing continuous venovenous haemodialysis are shown 
by filled symbols. Figure reproduced from Sandri et al. [29] with permission. Published 
2013 by Oxford University Press.
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Fig. 4. 
Relationship between bacterial load in the thighs of neutropenic mice at 24 h and the ratio of 
the area under the unbound (free) concentration–time curve to the MIC (fAUC/MIC) of 
colistin for Pseudomonas aeruginosa ATCC 27853. Figure adapted from Cheah et al. [23] 
with permission. Published 2015 by Oxford University Press.
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